OXILAN-300
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXILAN-300 is a small-molecule injectable approved in 1995 by Guerbet. The specific indication and mechanism of action are not publicly detailed in available data, but the product is administered via injection. This mature product is currently approaching loss of exclusivity.
LOE Approaching
As LOE approaches, the brand team is likely consolidating operations and shifting focus toward defending market share or managing decline; headcount may stabilize or contract.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OXILAN-300 offers limited career growth potential given the LOE-approaching lifecycle stage and zero linked job openings. Roles available are typically focused on managed decline, pricing strategy, and competitive defense rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on OXILAN-300 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.